Purple Biotech (PPBT) Liabilities and Shareholders Equity (2018 - 2021)

Purple Biotech (PPBT) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $70.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 16.23% to $70.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $183.4 million, a 61.99% increase, with the full-year FY2021 number at $70.2 million, down 16.23% from a year prior.
  • Liabilities and Shareholders Equity was $70.2 million for Q4 2021 at Purple Biotech, down from $83.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $83.8 million in Q4 2020 to a low of $14.7 million in Q4 2019.
  • A 4-year average of $45.9 million and a median of $42.5 million in 2018 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 469.39% in 2020, then dropped 16.23% in 2021.
  • Purple Biotech's Liabilities and Shareholders Equity stood at $14.7 million in 2018, then fell by 0.03% to $14.7 million in 2019, then skyrocketed by 469.39% to $83.8 million in 2020, then decreased by 16.23% to $70.2 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Liabilities and Shareholders Equity are $70.2 million (Q4 2021), $83.8 million (Q4 2020), and $14.7 million (Q4 2019).